FcrR3A-158 Polymorphism and Stromal Tumor-Infiltrating Lymphocytes and Survival among Patients with Metastatic HER2-Positive Breast Cancer Receiving Trastuzumab-Based Treatment.

Conclusion: High sTIL expression may be associated with better efficacy of trastuzumab-containing therapy in patients with metastatic HER2-positive breast cancer. However, this finding warrants further evaluation in the larger population. PMID: 29628983 [PubMed]

https://www.ncbi.nlm.nih.gov/pubmed/29628983?dopt=Abstract

Source: Journal of Breast Cancer - April 11, 2018 Category: Cancer & Oncology Tags: J Breast Cancer Source Type: research